176 related articles for article (PubMed ID: 19191868)
21. Prevention of myeloma cell apoptosis by ectopic bcl-2 expression or interleukin 6-mediated up-regulation of bcl-xL.
Schwarze MM; Hawley RG
Cancer Res; 1995 Jun; 55(11):2262-5. PubMed ID: 7757973
[TBL] [Abstract][Full Text] [Related]
22. Bcl3 Phosphorylation by Akt, Erk2, and IKK Is Required for Its Transcriptional Activity.
Wang VY; Li Y; Kim D; Zhong X; Du Q; Ghassemian M; Ghosh G
Mol Cell; 2017 Aug; 67(3):484-497.e5. PubMed ID: 28689659
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiling of bone marrow endothelial cells in patients with multiple myeloma.
Ria R; Todoerti K; Berardi S; Coluccia AM; De Luisi A; Mattioli M; Ronchetti D; Morabito F; Guarini A; Petrucci MT; Dammacco F; Ribatti D; Neri A; Vacca A
Clin Cancer Res; 2009 Sep; 15(17):5369-78. PubMed ID: 19690192
[TBL] [Abstract][Full Text] [Related]
24. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
25. Serum/glucocorticoid-regulated kinase 1 (SGK1) is a prominent target gene of the transcriptional response to cytokines in multiple myeloma and supports the growth of myeloma cells.
Fagerli UM; Ullrich K; Stühmer T; Holien T; Köchert K; Holt RU; Bruland O; Chatterjee M; Nogai H; Lenz G; Shaughnessy JD; Mathas S; Sundan A; Bargou RC; Dörken B; Børset M; Janz M
Oncogene; 2011 Jul; 30(28):3198-206. PubMed ID: 21478911
[TBL] [Abstract][Full Text] [Related]
26. Role of bcl-X(L) in the control of apoptosis in murine myeloma cells.
Gauthier ER; Piché L; Lemieux G; Lemieux R
Cancer Res; 1996 Mar; 56(6):1451-6. PubMed ID: 8640839
[TBL] [Abstract][Full Text] [Related]
27. AML-1A and AML-1B regulation of MIP-1alpha expression in multiple myeloma.
Choi SJ; Oba T; Callander NS; Jelinek DF; Roodman GD
Blood; 2003 May; 101(10):3778-83. PubMed ID: 12560229
[TBL] [Abstract][Full Text] [Related]
28. Reappraisal of BCL3 as a molecular marker of anaplastic large cell lymphoma.
Ohno H; Nishikori M; Maesako Y; Haga H
Int J Hematol; 2005 Dec; 82(5):397-405. PubMed ID: 16533741
[TBL] [Abstract][Full Text] [Related]
29. Expression and Clinical Significance of BCL2 Interacting Protein 3 Like in Multiple Myeloma.
Li R; Chen G; Dang Y; He R; Liu A; Ma J; Ling Z
Technol Cancer Res Treat; 2021; 20():15330338211024551. PubMed ID: 34189969
[TBL] [Abstract][Full Text] [Related]
30. Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.
Yu T; Du C; Ma X; Sui W; Yu Z; Liu L; Zhao L; Li Z; Xu J; Wei X; Zhou W; Deng S; Zou D; An G; Tai YT; Tricot G; Anderson KC; Qiu L; Zhan F; Hao M
Mol Cancer Res; 2020 Jul; 18(7):1063-1073. PubMed ID: 32312841
[TBL] [Abstract][Full Text] [Related]
31. Long Noncoding RNA
Handa H; Honma K; Oda T; Kobayashi N; Kuroda Y; Kimura-Masuda K; Watanabe S; Ishihara R; Murakami Y; Masuda Y; Tahara KI; Takei H; Kasamatsu T; Saitoh T; Murakami H
Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992461
[TBL] [Abstract][Full Text] [Related]
32. Aspirin inhibits proliferation and induces apoptosis of multiple myeloma cells through regulation of Bcl-2 and Bax and suppression of VEGF.
Ding JH; Yuan LY; Huang RB; Chen GA
Eur J Haematol; 2014 Oct; 93(4):329-39. PubMed ID: 24766194
[TBL] [Abstract][Full Text] [Related]
33. Establishment and characterization of three myeloma cell lines that demonstrate variable cytokine responses and abilities to produce autocrine interleukin-6.
Westendorf JJ; Ahmann GJ; Greipp PR; Witzig TE; Lust JA; Jelinek DF
Leukemia; 1996 May; 10(5):866-76. PubMed ID: 8656685
[TBL] [Abstract][Full Text] [Related]
34. Expression Of Intracellular Components of the NF-κB Alternative Pathway (NF-κB2, RelB, NIK and Bcl3) is Associated With Clinical Outcome of NSCLC Patients.
Dimitrakopoulos FD; Antonacopoulou AG; Kottorou AE; Panagopoulos N; Kalofonou F; Sampsonas F; Scopa C; Kalofonou M; Koutras A; Makatsoris T; Dougenis D; Papadaki H; Brock M; Kalofonos HP
Sci Rep; 2019 Oct; 9(1):14299. PubMed ID: 31586084
[TBL] [Abstract][Full Text] [Related]
35. MTDH is an oncogene in multiple myeloma, which is suppressed by Bortezomib treatment.
Gu C; Feng L; Peng H; Yang H; Feng Z; Yang Y
Oncotarget; 2016 Jan; 7(4):4559-69. PubMed ID: 26683226
[TBL] [Abstract][Full Text] [Related]
36. miR-215-5p is an anticancer gene in multiple myeloma by targeting RUNX1 and deactivating the PI3K/AKT/mTOR pathway.
Liu S; Zhang Y; Huang C; Lin S
J Cell Biochem; 2020 Feb; 121(2):1475-1490. PubMed ID: 31498483
[TBL] [Abstract][Full Text] [Related]
37. ZHX2 mediates proteasome inhibitor resistance via regulating nuclear translocation of NF-κB in multiple myeloma.
Jiang J; Sun Y; Xu J; Xu T; Xu Z; Liu P
Cancer Med; 2020 Oct; 9(19):7244-7252. PubMed ID: 32780537
[TBL] [Abstract][Full Text] [Related]
38. IL-6-induced Bcl6 variant 2 supports IL-6-dependent myeloma cell proliferation and survival through STAT3.
Tsuyama N; Danjoh I; Otsuyama K; Obata M; Tahara H; Ohta T; Ishikawa H
Biochem Biophys Res Commun; 2005 Nov; 337(1):201-8. PubMed ID: 16188230
[TBL] [Abstract][Full Text] [Related]
39. BCL3 Expression Is a Potential Prognostic and Predictive Biomarker in Acute Myeloid Leukemia of FAB Subtype M2.
Niu Y; Yang X; Chen Y; Zhang L; Jin X; Tang Y; Li L; Yu L; Guo Y; Wang H
Pathol Oncol Res; 2019 Apr; 25(2):541-548. PubMed ID: 30357752
[TBL] [Abstract][Full Text] [Related]
40. Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth.
Tatetsu H; Ueno S; Hata H; Yamada Y; Takeya M; Mitsuya H; Tenen DG; Okuno Y
Cancer Res; 2007 Jun; 67(11):5328-36. PubMed ID: 17545613
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
